ECSP099580A - Sales 668 - Google Patents
Sales 668Info
- Publication number
- ECSP099580A ECSP099580A EC2009009580A ECSP099580A ECSP099580A EC SP099580 A ECSP099580 A EC SP099580A EC 2009009580 A EC2009009580 A EC 2009009580A EC SP099580 A ECSP099580 A EC SP099580A EC SP099580 A ECSP099580 A EC SP099580A
- Authority
- EC
- Ecuador
- Prior art keywords
- ethyl
- sales
- dibromhydrate
- benzothiazol
- propanamide
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
- C07D277/62—Benzothiazoles
- C07D277/68—Benzothiazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/428—Thiazoles condensed with carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Otolaryngology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Thiazole And Isothizaole Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
Una sal farmacéuticamente aceptable de N-[2-(dietilamino)etil]-N-(2-{[2-(4-hidroxi-2-oxo-2,3-dihidro-1,3-benzotiazol-7-il)etil]amino}etil)-3-[2-(1-naftil)etoxi]propanamida siempre que no sea la sal dibromhidrato o diclorhidrato; y el uso de tal compuesto como un medicamento (por ejemplo, en el tratamiento de enfermedades respiratorias (tales como asma EPOC)).
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB0702458.1A GB0702458D0 (en) | 2007-02-08 | 2007-02-08 | Salts 668 |
Publications (1)
Publication Number | Publication Date |
---|---|
ECSP099580A true ECSP099580A (es) | 2009-09-29 |
Family
ID=37898978
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EC2009009580A ECSP099580A (es) | 2007-02-08 | 2009-08-14 | Sales 668 |
Country Status (20)
Country | Link |
---|---|
US (2) | US20100093813A1 (es) |
EP (1) | EP2118084A1 (es) |
JP (1) | JP2010518057A (es) |
KR (1) | KR20090107054A (es) |
CN (1) | CN101605770A (es) |
AR (1) | AR065278A1 (es) |
AU (1) | AU2008212714A1 (es) |
BR (1) | BRPI0807727A2 (es) |
CA (1) | CA2675994A1 (es) |
CL (1) | CL2008000399A1 (es) |
CO (1) | CO6241151A2 (es) |
EC (1) | ECSP099580A (es) |
GB (1) | GB0702458D0 (es) |
IL (1) | IL199913A0 (es) |
MX (1) | MX2009008371A (es) |
PE (1) | PE20090646A1 (es) |
RU (1) | RU2009133254A (es) |
TW (1) | TW200845970A (es) |
UY (1) | UY30903A1 (es) |
WO (1) | WO2008096112A1 (es) |
Families Citing this family (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TW200738658A (en) * | 2005-08-09 | 2007-10-16 | Astrazeneca Ab | Novel compounds |
TW200738659A (en) * | 2005-08-29 | 2007-10-16 | Astrazeneca Ab | Novel compounds |
TW200745067A (en) | 2006-03-14 | 2007-12-16 | Astrazeneca Ab | Novel compounds |
US7858663B1 (en) * | 2007-10-31 | 2010-12-28 | Pisgah Laboratories, Inc. | Physical and chemical properties of thyroid hormone organic acid addition salts |
TW200833670A (en) * | 2006-12-20 | 2008-08-16 | Astrazeneca Ab | Novel compounds 569 |
GB0702458D0 (en) | 2007-02-08 | 2007-03-21 | Astrazeneca Ab | Salts 668 |
UY31905A (es) | 2008-06-18 | 2010-01-29 | Astrazeneca Ab | Derivados de benzoxazinona, procesos de preparación, composiciones farmacéuticas conteniéndolos y aplicaciones. |
JP5079880B2 (ja) | 2008-06-27 | 2012-11-21 | 京セラ株式会社 | 無線通信装置及び無線通信方法 |
US8236786B2 (en) | 2008-08-07 | 2012-08-07 | Pulmagen Therapeutics (Inflammation) Limited | Respiratory disease treatment |
WO2010150014A1 (en) | 2009-06-24 | 2010-12-29 | Pulmagen Therapeutics (Inflammation) Limited | 5r- 5 -deuterated glitazones for respiratory disease treatment |
WO2011061527A1 (en) | 2009-11-17 | 2011-05-26 | Astrazeneca Ab | Combinations comprising a glucocorticoid receptor modulator for the treatment of respiratory diseases |
WO2011098746A1 (en) | 2010-02-09 | 2011-08-18 | Pulmagen Therapeutics (Inflammation) Limited | Crystalline acid addition salts of ( 5r) -enanti0mer of pioglitazone |
GB201002224D0 (en) | 2010-02-10 | 2010-03-31 | Argenta Therapeutics Ltd | Respiratory disease treatment |
GB201002243D0 (en) | 2010-02-10 | 2010-03-31 | Argenta Therapeutics Ltd | Respiratory disease treatment |
PL3617199T3 (pl) * | 2017-04-28 | 2024-01-22 | Fuji Yakuhin Co., Ltd. | Postać krystaliczna i sól 3-(3,5-dichloro-4-hydroksybenzoilo)-1,1-diokso-2,3-dihydro-1,3- benzotiazolu |
Family Cites Families (74)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2653977A (en) * | 1953-09-29 | Chxnx | ||
US3775477A (en) * | 1971-03-10 | 1973-11-27 | Sterling Drug Inc | N,n'-bis(2-aryl-2-(hydroxy or oxo)-ethyl)-bridged-bis-carboxamides |
US4460581A (en) * | 1982-10-12 | 1984-07-17 | Boehringer Ingelheim Kg | (1-Hydroxy-2-amino-alkyl)-substituted benzoxazinones and benzoxazolinones |
EP0162576B1 (en) | 1984-04-17 | 1989-07-26 | Glaxo Group Limited | Ethanolamine compounds |
US4554287A (en) | 1984-09-12 | 1985-11-19 | Smithkline Beckman Corporation | Antihypertensive 7-[2-(dialkylamino)ethyl]-4-hydroxy-1,3-benzimidazol-2-ones |
US4554284A (en) | 1984-09-12 | 1985-11-19 | Smithkline Beckman Corporation | 7-(2-Aminoethyl)-1,3-benzthia- or oxa-zol-2(3H)-ones |
GB8525483D0 (en) | 1985-10-16 | 1985-11-20 | Glaxo Group Ltd | Chemical compounds |
GB8718938D0 (en) | 1987-08-11 | 1987-09-16 | Glaxo Group Ltd | Chemical compounds |
TW209832B (es) | 1989-10-10 | 1993-07-21 | Glaxo Group Ltd | |
US5648370A (en) * | 1990-11-20 | 1997-07-15 | Astra Pharmaceuticals Limited | 7-(2-aminoethyl) benzothiazolones |
GB9211172D0 (en) | 1992-05-27 | 1992-07-08 | Fisons Plc | Compounds |
IE914003A1 (en) | 1990-11-20 | 1992-05-20 | Astra Pharma Prod | Biologically Active Amines |
GB9210632D0 (en) | 1992-05-19 | 1992-07-01 | Fisons Plc | Compounds |
TW356468B (en) | 1995-09-15 | 1999-04-21 | Astra Pharma Prod | Benzothiazolone compounds useful as beta2-adrenoreceptor and dopamine DA2 receptor agonists process for preparing same and pharmaceutical compositions containing same |
GB9526511D0 (en) | 1995-12-23 | 1996-02-28 | Astra Pharma Prod | Pharmaceutically active compounds |
DE69709647T2 (de) | 1996-05-20 | 2002-11-07 | Dupont Pharmaceuticals Research Laboratories, Inc. | Cyclischer diarylalkyl diaminederivate als antogoniste von chemokinerezeptoren |
SE9700706D0 (sv) | 1997-02-27 | 1997-02-27 | Astra Pharma Prod | Process for the preparation of benzothiazoline compounds |
SE9701304D0 (sv) | 1997-04-09 | 1997-04-09 | Astra Pharma Prod | Compounds |
AU2081999A (en) | 1998-01-13 | 1999-08-02 | Astrazeneca Uk Limited | Pharmaceutical compostition comprising a compound having dopamine (D2) receptor agonist activity and a compound (B) having Beta2 adrenoreceptor agonist activity |
US6362371B1 (en) | 1998-06-08 | 2002-03-26 | Advanced Medicine, Inc. | β2- adrenergic receptor agonists |
GB9913083D0 (en) | 1999-06-04 | 1999-08-04 | Novartis Ag | Organic compounds |
US6683115B2 (en) * | 1999-06-02 | 2004-01-27 | Theravance, Inc. | β2-adrenergic receptor agonists |
SE9902935D0 (sv) | 1999-08-18 | 1999-08-18 | Astra Pharma Prod | Pharmaceutical compositions |
SE9902938D0 (sv) | 1999-08-18 | 1999-08-18 | Astra Pharma Prod | Pharmaceutical compositions |
SE9902936D0 (sv) | 1999-08-18 | 1999-08-18 | Astra Pharma Prod | Pharmaceutical compositions |
SE9902937D0 (sv) | 1999-08-18 | 1999-08-18 | Astra Pharma Prod | Pharmaceutical compositions |
OA11558A (en) | 1999-12-08 | 2004-06-03 | Advanced Medicine Inc | Beta 2-adrenergic receptor agonists. |
US6506901B2 (en) | 2000-07-17 | 2003-01-14 | Wyeth | Substituted 2-(S)-hydroxy-3-(piperidin-4-yl-methylamino)-propyl ethers and substituted 2-aryl-2-(R)-hydroxy-1-(piperidin-4-yl-methyl)-ethylamine β-3 adrenergic receptor agonists |
JP4143413B2 (ja) | 2001-03-22 | 2008-09-03 | グラクソ グループ リミテッド | β2−アドレナリン受容体アゴニストとしてのホルムアニリド誘導体 |
PT1425001E (pt) | 2001-09-14 | 2009-02-18 | Glaxo Group Ltd | Derivados de fenetanolamina para o tratamento de doenças respiratórias |
US20030229058A1 (en) * | 2001-11-13 | 2003-12-11 | Moran Edmund J. | Aryl aniline beta2 adrenergic receptor agonists |
GB0217225D0 (en) | 2002-07-25 | 2002-09-04 | Glaxo Group Ltd | Medicinal compounds |
AR040962A1 (es) | 2002-08-09 | 2005-04-27 | Novartis Ag | Compuestos derivados de tiazol 1,3-2-ona, composicion farmaceutica y proceso de preparacion del compuesto |
GB0225540D0 (en) | 2002-11-01 | 2002-12-11 | Glaxo Group Ltd | Medicinal compounds |
PE20040950A1 (es) | 2003-02-14 | 2005-01-01 | Theravance Inc | DERIVADOS DE BIFENILO COMO AGONISTAS DE LOS RECEPTORES ADRENERGICOS ß2 Y COMO ANTAGONISTAS DE LOS RECEPTORES MUSCARINICOS |
GB0303396D0 (en) | 2003-02-14 | 2003-03-19 | Glaxo Group Ltd | Medicinal compounds |
JP4767842B2 (ja) | 2003-04-01 | 2011-09-07 | セラヴァンス, インコーポレーテッド | β2アドレナリン作用性レセプターアゴニスト活性およびムスカリン性レセプターアンタゴニスト活性を有するジアリールメチル化合物および関連化合物 |
TW200526547A (en) | 2003-09-22 | 2005-08-16 | Theravance Inc | Amino-substituted ethylamino β2 adrenergic receptor agonists |
GB0324654D0 (en) | 2003-10-22 | 2003-11-26 | Glaxo Group Ltd | Medicinal compounds |
GB0324886D0 (en) | 2003-10-24 | 2003-11-26 | Glaxo Group Ltd | Medicinal compounds |
JP2005187357A (ja) | 2003-12-25 | 2005-07-14 | Nippon Suisan Kaisha Ltd | 選択的なβ2受容体アゴニスト活性を有するベンゾチアゾロン誘導体の製造方法 |
TW200531692A (en) | 2004-01-12 | 2005-10-01 | Theravance Inc | Aryl aniline derivatives as β2 adrenergic receptor agonists |
GB0402797D0 (en) | 2004-02-09 | 2004-03-10 | Novartis Ag | Organic compounds |
WO2005092861A1 (en) | 2004-03-11 | 2005-10-06 | Pfizer Limited | Quinolinone derivatives pharmaceutical compositions containing them and their use |
EP1577306A1 (de) | 2004-03-17 | 2005-09-21 | Boehringer Ingelheim Pharma GmbH & Co.KG | Neue Benzoxazinonderivate als langwirksame Betamimetika zur Behandlung von Atemwegserkrankungen |
WO2005092841A1 (en) | 2004-03-23 | 2005-10-06 | Pfizer Limited | Compounds having beta-agonist activity |
CA2565243A1 (en) | 2004-05-13 | 2005-11-24 | Boehringer Ingelheim International Gmbh | Hydroxy-substituted benzo-condensed heterocycles for use as beta agonists in the treatment of respiratory diseases |
EP1595873A1 (de) | 2004-05-13 | 2005-11-16 | Boehringer Ingelheim Pharma GmbH & Co.KG | Substituierte Cycloalkylderivate zur Behandlung von Atemswegerkrankungen |
DE102004024453A1 (de) | 2004-05-14 | 2006-01-05 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue langwirksame Bronchodilatoren zur Behandlung von Atemwegserkrankungen |
BRPI0511695A (pt) | 2004-06-03 | 2008-01-08 | Theravance Inc | agonistas de receptor (beta)2 adrenérgico diamina |
JP2008507532A (ja) | 2004-07-21 | 2008-03-13 | セラヴァンス, インコーポレーテッド | ジアリールエーテルβ2アドレナリン作用性レセプターアゴニスト |
EP1778626A1 (en) | 2004-08-16 | 2007-05-02 | Theravance, Inc. | Compounds having beta2 adrenergic receptor agonist and muscarinic receptor antagonist activity |
WO2006023460A2 (en) | 2004-08-16 | 2006-03-02 | Theravance, Inc. | COMPOUNDS HAVING β2 ADRENERGIC RECEPTOR AGONIST AND MUSCARINIC RECEPTOR ANTAGONIST ACTIVITY |
EP1786762A2 (en) | 2004-09-10 | 2007-05-23 | Theravance, Inc. | Amidine substituted aryl aniline compounds |
GB0426164D0 (en) | 2004-11-29 | 2004-12-29 | Novartis Ag | Organic compounds |
JP2008526805A (ja) | 2005-01-11 | 2008-07-24 | グラクソ グループ リミテッド | ベータ−2アドレナリン作動薬のケイヒ酸塩 |
GB0511066D0 (en) | 2005-05-31 | 2005-07-06 | Novartis Ag | Organic compounds |
NZ585580A (en) | 2005-07-18 | 2011-08-26 | Pfizer Ltd | Process for the preparation of sulfonamide derivatives |
TW200738658A (en) * | 2005-08-09 | 2007-10-16 | Astrazeneca Ab | Novel compounds |
TW200738659A (en) * | 2005-08-29 | 2007-10-16 | Astrazeneca Ab | Novel compounds |
TW200740781A (en) | 2005-08-29 | 2007-11-01 | Astrazeneca Ab | Novel compounds |
US20090029958A1 (en) * | 2006-03-08 | 2009-01-29 | Lilian Alcaraz | Phenethanolamine derivatives as beta2 adrenoreceptor agonists |
TW200745084A (en) | 2006-03-08 | 2007-12-16 | Astrazeneca Ab | Novel compounds |
TW200745067A (en) * | 2006-03-14 | 2007-12-16 | Astrazeneca Ab | Novel compounds |
WO2008041914A1 (en) | 2006-10-06 | 2008-04-10 | Astrazeneca Ab | 5-(2-AMINO-L-HYDROXYETHYL)-8-HYDROXY-2-OXOQUINOLINE DERIVATIVES AND OTHER COMPOUNDS AS β2 -ADRENERGIC AGONISTS |
CA2672792A1 (en) | 2006-12-20 | 2008-06-26 | Astrazeneca Ab | Amine derivatives and their use in beta-2-adrenoreceptor mediated diseases |
TW200833670A (en) * | 2006-12-20 | 2008-08-16 | Astrazeneca Ab | Novel compounds 569 |
GB0702457D0 (en) | 2007-02-08 | 2007-03-21 | Astrazeneca Ab | New combination 666 |
GB0702458D0 (en) | 2007-02-08 | 2007-03-21 | Astrazeneca Ab | Salts 668 |
GB0702456D0 (en) | 2007-02-08 | 2007-03-21 | Astrazeneca Ab | New combination |
GB0702459D0 (en) | 2007-02-08 | 2007-03-21 | Astrazeneca Ab | Salts 669 |
GB0704000D0 (en) | 2007-03-01 | 2007-04-11 | Astrazeneca Ab | Salts 670 |
GB0703999D0 (en) | 2007-03-01 | 2007-04-11 | Astrazeneca Ab | New combination 667 |
WO2009037503A2 (en) | 2007-09-18 | 2009-03-26 | Astrazeneca Ab | New combination - 012 for the treatment of respiratory diseases |
-
2007
- 2007-02-08 GB GBGB0702458.1A patent/GB0702458D0/en not_active Ceased
-
2008
- 2008-02-04 TW TW097104218A patent/TW200845970A/zh unknown
- 2008-02-06 CA CA002675994A patent/CA2675994A1/en not_active Abandoned
- 2008-02-06 KR KR1020097016586A patent/KR20090107054A/ko not_active Application Discontinuation
- 2008-02-06 RU RU2009133254/04A patent/RU2009133254A/ru not_active Application Discontinuation
- 2008-02-06 WO PCT/GB2008/000387 patent/WO2008096112A1/en active Application Filing
- 2008-02-06 MX MX2009008371A patent/MX2009008371A/es unknown
- 2008-02-06 US US12/526,331 patent/US20100093813A1/en not_active Abandoned
- 2008-02-06 JP JP2009548731A patent/JP2010518057A/ja not_active Withdrawn
- 2008-02-06 CN CNA2008800046169A patent/CN101605770A/zh active Pending
- 2008-02-06 EP EP08702048A patent/EP2118084A1/en not_active Withdrawn
- 2008-02-06 AU AU2008212714A patent/AU2008212714A1/en not_active Abandoned
- 2008-02-06 BR BRPI0807727-4A patent/BRPI0807727A2/pt not_active IP Right Cessation
- 2008-02-07 PE PE2008000271A patent/PE20090646A1/es not_active Application Discontinuation
- 2008-02-07 US US12/069,180 patent/US8058294B2/en not_active Expired - Fee Related
- 2008-02-07 CL CL200800399A patent/CL2008000399A1/es unknown
- 2008-02-08 AR ARP080100561A patent/AR065278A1/es not_active Application Discontinuation
- 2008-02-08 UY UY30903A patent/UY30903A1/es not_active Application Discontinuation
-
2009
- 2009-07-16 IL IL199913A patent/IL199913A0/en unknown
- 2009-07-28 CO CO09078486A patent/CO6241151A2/es not_active Application Discontinuation
- 2009-08-14 EC EC2009009580A patent/ECSP099580A/es unknown
Also Published As
Publication number | Publication date |
---|---|
JP2010518057A (ja) | 2010-05-27 |
RU2009133254A (ru) | 2011-03-20 |
PE20090646A1 (es) | 2009-06-26 |
WO2008096112A1 (en) | 2008-08-14 |
TW200845970A (en) | 2008-12-01 |
CN101605770A (zh) | 2009-12-16 |
UY30903A1 (es) | 2008-09-30 |
AU2008212714A1 (en) | 2008-08-14 |
CO6241151A2 (es) | 2011-01-20 |
GB0702458D0 (en) | 2007-03-21 |
US20100093813A1 (en) | 2010-04-15 |
US8058294B2 (en) | 2011-11-15 |
CL2008000399A1 (es) | 2008-10-24 |
US20080249145A1 (en) | 2008-10-09 |
IL199913A0 (en) | 2010-04-15 |
AR065278A1 (es) | 2009-05-27 |
EP2118084A1 (en) | 2009-11-18 |
BRPI0807727A2 (pt) | 2014-06-03 |
KR20090107054A (ko) | 2009-10-12 |
CA2675994A1 (en) | 2008-08-14 |
MX2009008371A (es) | 2009-08-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ECSP099580A (es) | Sales 668 | |
ECSP099476A (es) | Compuestos carboxamida y su uso como inhibidores de calpaína | |
HRP20110695T1 (hr) | Kombinacije beta-2-adrenoceptorskog agonističkog benzotiazolona | |
ECSP11010948A (es) | Inhibidores de las enzimas de proteína cinasa activadas por | |
UY28885A1 (es) | 4-fenilamino-quinazolin-6-il-amidas referencia cruzada a solicitud(es) relacionada(s) | |
RS53209B (en) | PHARMACEUTICAL COMPOSITION FOR VIRAL HEPATITIS C PROTEASE INHIBITOR | |
CL2012001449A1 (es) | Uso de combinaciones del compuesto n-[(ciclopentiloxi)carbonil]-3-metil-l-valiol-(4r)-4-({8-bromo-2-[2-(isobutirilamino)-1,3-tiazol-4-il]-7-metoxi-4-quinolinil}oxi)-n-[(1r,2s)-1-carboxi-2-vinilciclopropil]-l-prolinamida; y envase que comprende las formas de dosificacion. | |
ECSP10010265A (es) | Sales farmaceuticamente aceptables de (3-{[[3-(6-amino-2-butoxi-8-oxo-7,8 dihidro-9h-purin-9-il)propil](3-morfolin-4 ilpropil)amino]metil}fenil) | |
AR076388A1 (es) | Procedimientos para mejorar la farmocinetica | |
CL2013003360A1 (es) | “compuestos derivados de 4-aril-n-[3-(sulfonimidoil)fenil]-1,3,5-triazin-2-amina sustituidos, inhibidores cdk; compuestos intermediarios, composición y combinación farmacéutica que los comprende; y su uso en el tratamiento de enfermedades hiperproliferativas, infecciosas inducidas por virus y/o cardiovasculares”. pct | |
NZ579296A (en) | Spirocyclic compounds as inhibitors of serine proteases for the treatment of HCV infections | |
UY30809A1 (es) | Derivados de n-[3-[4-fenil)piperidin-1-carbonil]fenil]sulfonamidas sustituidas, procesos de preparacion y aplicaciones | |
ECSP099436A (es) | Acilaminopirazoles como inhibidores de fgfr | |
CL2011000571A1 (es) | Uso de una combinacion de: a) un compuesto de formula (1) o una sal farmaceuticamente aceptable del mismo, b) interferon alfa y c) ribavirina para preparar un medicamento util para el tratamiento de una infeccion viral de la hepatitis c (hcv) o para aliviar uno o mas sintomas de la misma. | |
CL2008001005A1 (es) | Compuestos derivados de azufre, inhibidores de la serina proteasa ns3 del virus de la hepatitis c; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de trastornos asociados a la proteasa de hcv. | |
MX2010008523A (es) | Inhibidores macrociclicos de serina proteasa. | |
NO20073900L (no) | Anvendelse av LGG for fremstilling av et medikament for forebygging eller behandling av respiratoriske sykdommer | |
MY148459A (en) | Use of benzo-fused heterocycle sulfamide derivatives for the treatment of depression | |
CL2009000198A1 (es) | Compuestos derivados del acido {2'-[(amino n,n-disustituido)-metil]-bifenil-3-il} acetico, mediadores de prostaglandina d2; composicion farmaceutica que los comprende; y su uso en el tratamiento de una enfermedad respiratoria, alergica o inflamatoria, tal como el asma, epoc o rinitis alergica. | |
WO2008069917A3 (en) | Novel cyclic peptides | |
CO6470862A2 (es) | Compuestos carboxamida y su uso como inhibidores de calpaina | |
CL2014002558A1 (es) | Sales de 5-[(1r)-2-([2-[4-(2,2-difluoro-2-feniletoxi)fenil]etil]amino)-1-hidroxietil]-8-hidroxiquinolin-2(1h)-ona; composicion y combinacion farmaceutica que las comprende y uso en el tratamiento del asma o epoc. | |
NI201000051A (es) | Benzotiazoles como moduladores del receptor de grelina. | |
UA102414C2 (ru) | Циклоундекадепсипептидные соединения для лечения инфекций, вызванных вирусом гепатита с | |
DE602006005640D1 (de) | 4-phenyl-5-oxo-1,4,5,6,7,8-hexahydrochinolin-derivate als arzneimittel zur behandlung von unfruchtbarkeit |